Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer. Kaakour is ...
The FDA has approved a label update for nadofaragene firadenovec-vncg (Adstiladrin), introducing an accelerated thawing protocol that may reduce preparation time for intravesical administration of the ...
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant ...
LITESPARK-011 randomized 747 patients post–anti–PD-(L)1 therapy to belzutifan/lenvatinib vs cabozantinib, with dual primary endpoints of BICR-assessed PFS and OS and key secondary ORR. Interim ...
FDA sNDAs seek approval of belzutifan plus lenvatinib for post–PD-1/PD-L1 advanced ccRCC, setting an October 4, 2026 PDUFA target action date. LITESPARK-011 randomized 747 patients to belzutifan 120 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results